Britain and America have signed a key trade agreement that will ensure zero levies on UK drug exports being sold in the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to boost spending on pharmaceuticals through the public health system. This commitment guarantees that import taxes on these vital products will stay at zero for a duration of 36 months.
This agreement comes after previous statements to hike import taxes on patented drug products, with increases discussed as high as 100%.
"This agreement with the Britain bolsters the international landscape for cutting-edge drugs and brings much-needed fairness to U.S.–U.K. pharmaceutical trade," a statement noted.
Commercial Significance
Medicines constitute one of the UK's biggest goods shipped to the US, which is by far the largest destination for major British pharmaceutical firms.
Export figures indicate that in the one-year period to the end of the third quarter, the UK shipped medicines worth billions to the US. This amount accounted for a significant portion of British export trade in that period.
"This guarantee protects jobs, boosts investment and facilitates the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary commented.
Key NHS Changes
The pact involves several key pledges from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to raise total public funding on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum manufacturers must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, repayments were more than twenty percent.
Recent Tensions
This agreement follows a ongoing row between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
These tensions were intensified by assertions that American patients were charged significantly more for the identical medicines than consumers in the Britain and the EU.
Recently, several significant drug company projects in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been directed toward US facilities.
A senior figure publicly accepted that the NHS must increase expenditure on medicines, noting that its budget allocation on drugs had declined as a proportion of its total funding over the previous ten-year period.
